MedPath

GSK's Depemokimab Shows Promise in Severe Asthma Treatment

• GSK's depemokimab demonstrated a statistically significant reduction in the annualised rate of asthma exacerbations compared to placebo in a Phase III trial. • The study focused on patients with severe asthma and type 2 inflammation, an area of significant unmet medical need. • These positive results support the potential of depemokimab as a novel treatment option for severe asthma, pending further regulatory review. • Depemokimab targets IL-5, offering a different approach to managing asthma symptoms and reducing exacerbation frequency.

GSK has announced positive results from a Phase III trial evaluating depemokimab for the treatment of severe asthma. The study demonstrated a statistically significant reduction in the annualised rate of asthma exacerbations in patients treated with depemokimab compared to those receiving a placebo.
The trial focused on patients with severe asthma characterized by type 2 inflammation. This subgroup often experiences frequent exacerbations and has limited treatment options, representing a significant unmet medical need. The positive results suggest that depemokimab could offer a new approach to managing this challenging condition.
Depemokimab is a novel monoclonal antibody that targets interleukin-5 (IL-5), a key cytokine involved in the inflammatory cascade that leads to asthma symptoms. By blocking IL-5, depemokimab aims to reduce eosinophil levels and subsequent airway inflammation, thereby decreasing the frequency and severity of asthma exacerbations.
The detailed data from the Phase III trial will be presented at an upcoming medical conference and submitted to regulatory authorities for review. If approved, depemokimab could provide a valuable new treatment option for patients with severe asthma and type 2 inflammation.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Laxxon Medical Announces Positive Pilot PK Study Results in Pigs for Groundbreaking Oral GLP-1 Dosage Form

Laxxon Medical has reported positive results from a pilot pharmacokinetic (PK) study conducted in pigs for an innovative oral GLP-1 dosage form, marking a significant step forward in the development of new treatment options.

GSK's Bepirovirsen Receives FDA Fast Track for Chronic Hepatitis B Treatment

The FDA has granted fast-track designation to GSK's bepirovirsen, an antisense drug, for chronic hepatitis B (CHB) treatment, expediting its review process.
Bepirovirsen is the only single agent in phase 3 trials showing potential for a functional cure when combined with standard nucleoside/nucleotide analogue (NA) therapies.

uniQure Receives FDA Nod for Accelerated Approval Pathway for Huntington's Disease Gene Therapy

uniQure secured FDA agreement to pursue accelerated approval for its Huntington's disease gene therapy, potentially expediting treatment availability.
The FDA's decision reflects a more flexible approach to genetic medicines for severe rare diseases under Peter Marks.

Hemogenyx Pharmaceuticals Initiates Patient Recruitment for AML Treatment Trial

Hemogenyx Pharmaceuticals has commenced patient recruitment for its Phase I clinical trial of a novel treatment for acute myeloid leukemia (AML).
The trial will assess the safety and efficacy of the treatment in patients with relapsed or refractory AML.

GSK's Linerixibat Shows Promise in Phase III Trial for PBC-Related Itch

GSK's linerixibat met its primary endpoint in a Phase III trial, demonstrating a statistically significant improvement in itch for patients with primary biliary cholangitis (PBC).
The GLISTEN trial included PBC patients with moderate to severe itch, with safety results aligning with previous studies, suggesting a well-tolerated profile.

Sareum's SDC-1801 Advances to Phase II Trials for Psoriasis Following Positive Phase I Results

Sareum Holdings is advancing its lead asset, SDC-1801, a dual TYK2/JAK1 inhibitor, into Phase II trials for psoriasis after completing Phase I trials in Australia.
Unblinded Phase I data demonstrated robust pharmacokinetic and pharmacodynamic properties, along with a favorable safety profile for SDC-1801.

Hemogenyx Pharmaceuticals Advances HEMO-CAR-T Therapy with New Funding and Clinical Trial Approvals

Hemogenyx Pharmaceuticals secured £600,000 to advance Phase I clinical trials for its HEMO-CAR-T therapy targeting acute myeloid leukemia.
The company received IRB approval and completed a site initiation visit, marking significant progress towards opening clinical trials.

Dimerix Advances Kidney Disease Trial with Key Endpoint Validation

Dimerix's PARASOL working group analysis supports using eGFR and proteinuria as key endpoints for FDA approval of kidney disease treatments.
The ongoing ACTION3 Phase 3 trial by Dimerix is gathering data on eGFR and proteinuria, potentially accelerating market approval.

GSK's Depemokimab Shows Promise in Reducing Severe Asthma Exacerbations

Depemokimab significantly reduced severe asthma attacks by 54% compared to placebo in Phase 3 trials, offering a potential new treatment option.
The ultra-long-acting biologic showed a 72% reduction in exacerbations requiring hospitalization or emergency department visits, highlighting its clinical impact.

GSK's Jesduvroq Receives FDA Approval for Anemia in Dialysis-Dependent CKD Patients

The FDA has approved GSK's Jesduvroq (roxadustat) for anemia treatment in adults with chronic kidney disease (CKD) who are on dialysis.
This approval is limited to dialysis-dependent patients, impacting the drug's market potential compared to a broader CKD indication.

Reference News

[1]
GSK reports positive results from depemokimab trial. - Research the market - Halifax
investments.halifax.co.uk · Oct 14, 2024

Halifax Share Dealing Limited is registered in England and Wales, authorized by the Financial Conduct Authority, and a m...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy